Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Canada Pharmaceuticals and Healthcare Report Q2 2008

Published by: Business Monitor International

Published: Apr. 22, 2008 - 70 Pages


Table of Contents


Executive Summary
Canada Pharmaceuticals And Healthcare Industry SWOT
Canada Political SWOT
Canada Economic SWOT
Pharmaceutical Business Environment Ratings
Table: Pharmaceutical Business Environment Rankings
Limits To Potential Returns
Risks To Realisation Of Returns
Canada - Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
Ontario Breaks The Mould
Industry Developments
Product Approvals And Launches
Pharmaceutical Re-import Policy
Company Activity
National Pharmaceuticals Strategy
Generics Sector
Table: Foreign-To-Canadian Price Ratios, 2005
Research And Development Sector
Pharmacy Sector
Industry Forecast Scenario
Overall Market Forecast
Table: Canada: Drug Market Indicators
Key Growth Factors - Industry
Table: Canadian Health Expenditure Indicators
Key Growth Factors - Macroeconomic
Table: Canada- Economic Activity
OTC Market Forecast
Table: Canadian OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated)
Generics Market Forecast
Table: Canadian Generics Market Indicators
Patented Market Forecast
Table: Canadian Patented Market Indicators
Export/Import Forecasts
Table: Sectoral Trade Indicators (US$mn)
Other Healthcare Data Forecasts
Table: Canadian Socio-demographic Indicators
Competitive Landscape
Table: Canada’s Leading Generics Firms, 2006
Company Profiles
Leading Multinational Manufacturers
Pfizer
Merck & Co
GlaxoSmithKline
Sanofi-Aventis
Novartis
Indigenous Manufacturers
Apotex
BMI Forecast Modelling.67
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Abstract

The Canadian drug market should continue its solid growth over the forecast period, driven by generous
public health expenditure and high per capita consumption. Canada’s investment in health should reach
12.8% in 2012 - one of the highest rates in the world, almost rivalling expenditure in the US even though
Canada’s drug spend is predominately state-based, as opposed to the system of private insurance
prevalent in the US. By 2012 total drug market spending in Canada should reach US$25.1bn.


Yet despite the high investment the Euro-Canada Health Consumer Index for 2008 places Canada 23rd out
of the 29 countries surveyed. A particular problem is poor access to medicines, which suggests that the
sector has more potential in terms of approving and prescribing innovative drugs. According to the Fraser
institute, a free-market think tank, patented drugs are significantly cheaper in Canada than in the US, but
because of the lack of market forces in the system, generic drugs are much more expensive. This can
result in Canadians actually spending a greeter proportion of their income on medication than their
counterparts in the US. There is also compelling evidence that suggests that American consumers have
greater access to the latest life-saving treatments than their Canadian counterparts, who rely on their
country’s public drug programmes.


Meanwhile, the province of Ontario is planning to plough CAD150mn (US$149mn) into the
pharmaceutical sector in a bid to boost employment levels. The money accounts for almost 10% of the
CAD1.15bn (US$1.1bn) ‘Next Generation Jobs Fund’, which is designed to attract investment and
employment in the province. BMI believes that local drugmakers will benefit from the funding with
research-based drugmakers permitted to apply for grants, loans, and no-interest financing for training,
research and infrastructure.


In BMI’s Business Environment Ranking for the Americas region, Canada remains in second place
behind the US. The country benefits from an advanced and sophisticated drug sector as well as a very
stable political and economic climate and low corruption. However, the country’s IP laws are frequently
criticised with ‘evergreening’ considered a particular problem.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options

Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008